A new study published in the Journal of Clinical Oncology reported on the clinical implications of gDDR genes.
Researchers identified two germline pathogenic variants in CHEK2 that may account for a minority of men diagnosed with testicular germ cell tumors.
An analysis of a large, phase III trial investigated a potential surrogate endpoint for survival outcomes in prostate cancer patients receiving ADT.
The findings of this study, recently published in JAMA Oncology, directly contradict previously conducted research on the same topic.
Oncologists now have some clarification on the use of moderate hypofractionation and ultrahypofractionation from ASTRO, ASCO, and the AUA.
A particular gatekeeper—the nuclear pore protein called POM121—traffics molecules that increase tumor aggressiveness in prostate cancer.